NCT02324166 arm group f326b44a9e9fe75efb22c432cc466093 [clinicaltrials_resource:NCT02324166/arm-group/f326b44a9e9fe75efb22c432cc466093]
arm group [clinicaltrials_vocabulary:arm-group]
NCT02324166 arm group f326b44a9e9fe75efb22c432cc466093 [clinicaltrials_resource:NCT02324166/arm-group/f326b44a9e9fe75efb22c432cc466093]
Bio2RDF identifier
NCT02324166/arm-group/f326b44a9e9fe75efb22c432cc466093
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 26b44a9e9fe75efb22c432cc466093
description [clinicaltrials_vocabulary:description]
For the control group, cefazol ...... he end of the retinal surgery.
identifier
clinicaltrials_resource:NCT02324166/arm-group/f326b44a9e9fe75efb22c432cc466093
title
NCT02324166 arm group f326b44a9e9fe75efb22c432cc466093
@en
type
label
NCT02324166 arm group f326b44a ...... 6b44a9e9fe75efb22c432cc466093]
@en